Get started
Oramed Pharmaceuticals Inc.Oramed Pharmaceuticals Inc.Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Technicals

ORMP chart

Key stats

Market capitalization
‪97.25 M‬USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
17.78
Basic EPS (TTM)
0.14USD
Net income
‪5.53 M‬USD
Revenue
‪1.34 M‬USD
Shares float
‪34.73 M‬
Beta (1Y)
1.74

About Oramed Pharmaceuticals Inc.

Sector
Health Technology
CEO
Nadav Kidron
Headquarters
New York
Website
oramed.com
Employees (FY)
15
Founded
2002
ISIN
US68403P2039
FIGI
BBG000LRYR36
Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It concentrates on the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in New York, NY.

Financials

Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

Ideas

See all ideas 

News

Keep reading

Technicals

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Stock brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of ORMP is 2.33 USD — it has decreased by 2.92% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Oramed Pharmaceuticals Inc. stocks are traded under the ticker ORMP.
Oramed Pharmaceuticals Inc. is going to release the next earnings report on May 29, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for Oramed Pharmaceuticals Inc. has a max estimate of 4.25 USD and a min estimate of 4.25 USD.
ORMP earnings for the last quarter are −0.08 USD whereas the estimation was −0.09 USD which accounts for 5.88% surprise. Estimated earnings for the next quarter are −0.12 USD. See more details about Oramed Pharmaceuticals Inc. earnings.
Oramed Pharmaceuticals Inc. revenue for the last quarter amounts to ‪700.00 K‬ USD despite the estimated figure of ‪700.00 K‬ USD. In the next quarter revenue is expected to reach ‪700.00 K‬ USD.
Yes, you can track Oramed Pharmaceuticals Inc. financials in yearly and quarterly reports right on TradingView.
Like other stocks, ORMP shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Oramed Pharmaceuticals Inc. stock right from TradingView charts — choose your broker and connect to your account.
ORMP reached its all-time high on Jan 13, 2014 with the price of 31.73 USD, and its all-time low was 0.09 USD and was reached on Apr 2, 2004.
See other stocks reaching their highest and lowest prices.
As of Apr 18, 2024, the company has 15.00 employees. See our rating of the largest employees — is Oramed Pharmaceuticals Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Oramed Pharmaceuticals Inc. EBITDA is ‪−15.57 M‬ USD, and current EBITDA margin is ‪−1.16 K‬%. See more stats in Oramed Pharmaceuticals Inc. financial statements.